Atlas Trials

Hormone Sensitive Prostate Cancer

16 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Hormone Sensitive Prostate Cancer

RecordFirmDate
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (NCT05352178)Universitaire Ziekenhuizen KU Leuven2022-04-20
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients (NCT06193993)National University Hospital, Singapore2021-11-30
A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer (NCT04995042)Jiangsu HengRui Medicine Co., Ltd.2021-09-24
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (NCT04335682)Alliance Foundation Trials, LLC.2021-08-17
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (NCT04493853)AstraZeneca2020-07-13
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (NCT04126070)Xiao X. Wei, MD2020-05-11
Cardiovascular Events in GnRH Agonist vs. Antagonist (NCT04182594)Rabin Medical Center2020-01-17
Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer (NCT04220398)RenJi Hospital2020-01-10
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients (NCT06473259)Santa Chiara Hospital2016-12-16
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) (NCT02319837)Pfizer2014-12-17

Track Hormone Sensitive Prostate Cancer automatically

Every clearance here is in the API, with alerts when new ones post.